Kidney Cancer Coverage from Every Angle
Advertisement
Advertisement

Published Medical Literature

New Biomarker in Clear Cell Kidney Cancer?
JAVELIN Solid Tumor Trial: Avelumab Monotherapy for Metastatic Kidney Cancer
Proteogenomics May Improve Diagnosis and Treatment of Kidney Cancer Subtype
Relationship Between Cancer and Mortality Outcomes in Chronic Kidney Disease
Nivolumab Plus Ipilimumab in Advanced Kidney Cancer: CheckMate 214 Update
Do Individuals With Psoriasis Have an Increased Risk for Kidney Cancer?
Toxicity-Based Titration of Axitinib in Metastatic Kidney Cancer
Sunitinib Followed by Second-Line Axitinib in Metastatic Renal Cell Carcinoma
Research Sheds Light on Oncogenes in Clear Cell Renal Cell Carcinoma
Role of Aryl Hydrocarbon Receptor Activation in Kidney Cancer/Disease
Potential Biomarker for Early-Stage Renal Cell Carcinoma
Long Noncoding RNA Signature: Useful Prognostic Tool in Renal Cell Carcinoma?
Stereotactic Ablative Radiotherapy for Oligometastatic Renal Cell Carcinoma
Case Study of ‘Long-Lasting’ Response to Nivolumab in Patient With BRCA1 Mutation
DYSF Expression: Biomarker in Clear Cell Renal Cell Carcinoma?
Update on Systemic Treatments and Sequences in Metastatic Kidney Cancer
Efficiency of Existing Prognostic Models in Renal Cell Carcinoma
Partial Versus Radical Nephrectomy in Elderly Patients With Renal Cancer
Study Finds Limited Activity With Immunotherapy for Brain Metastases From Kidney Cancer
First-Line Treatment With Atezolizumab Plus Bevacizumab Versus Sunitinib in Kidney Cancer
Tumor-Infiltrating Immune Cell Characteristics and Recurrence of Clear Cell Kidney Cancer
Collagen Organization in Low- and High-Grade Kidney Tumors
Does Targeted Therapy Improve Survival in Patients With Metastatic Renal Cell Carcinoma?
Immune-Related Adverse Events With Nivolumab: Predicting Outcomes in Kidney Cancer
Monitoring Patients With Kidney Cancer for Cabozantinib-Related Toxicity
Is the Relationship Between Obesity and Outcomes in Kidney Cancer Sex-Specific?
Can Bladder Cancer Be Detected With a Urine Test?
Is Percutaneous Cryoablation a Viable Option for T1b Renal Cell Carcinoma?
Predicting Response to Immunotherapy for Kidney Cancer With FDG-PET/CT
High-Dose IL-2 in Metastatic Kidney Cancer: Outcomes by Risk Groups
Current Status and Future Prospects of Kidney Cancer Treatment
First-Line Combination Therapy in Metastatic Kidney Cancer: Answers and More Questions
Does Tumor Thrombus Affect Outcomes With Cytoreductive Nephrectomy?
KEYNOTE-426 Trial: Pembrolizumab Plus Axitinib Versus Sunitinib in Advanced Kidney Cancer
Cabozantinib in Advanced Non–Clear Cell Kidney Cancer
Individualized Sunitinib Therapy for Patients With Metastatic Kidney Cancer
Tisotumab Vedotin Exhibits Antitumor Activity in Bladder Cancer, Among Other Cancers
Adding a Beta-Blocker to Immunotherapy in Kidney Cancers
JAVELIN Renal 101 Trial: Axitinib Plus Avelumab in Kidney Cancer
Is GRP78 Expression Useful Biomarker for Clear Cell Renal Cell Carcinoma?
Risk of Ovarian Cancer After Radical Cystectomy for Bladder Cancer
Patient-Reported Outcomes in Advanced Renal Cell Carcinoma
Phase I Study of Anti–PD-1 Antibody in Advanced Urologic Cancer
Does Axitinib Improve Outcomes in Favorable-Risk Patients With Metastatic Kidney Cancer?
Renal Function and Cancer-Specific Mortality in Renal Cell Carcinoma
Does Sunitinib Therapy Before Cytoreductive Nephrectomy Improve Outcomes in Metastatic Kidney Cancer?
Prognostic Marker for Non–Muscle-Invasive Bladder Cancer
Neoadjuvant Pembrolizumab Before Surgery in Muscle-Invasive Bladder Carcinoma
Combination of Paclitaxel, Sorafenib, and Radiation in Advanced Kidney Cancer
Combination Immunotherapy in First-Line Treatment of Advanced Kidney Cancer
Muscle-Invasive Bladder Cancer: Two Regimens, Two Successes in Phase II Trial
Using Hub Genes to Predict Outcomes in Clear Cell Kidney Cancer
Kidney Transplantation in Patients With Renal Cell Carcinoma: Defining When and Why
Can Changes in Skeletal Muscle Mass Predict Outcomes in Metastatic Kidney Cancer?
Genomic Alterations and Outcomes in Patients With Renal Cancer Receiving Everolimus
Combining TKIs and Immune Checkpoint Inhibitors in Advanced Kidney Cancer
Utilizing Team-Based Approach to Manage Complex Cases of Kidney Cancer
Choosing Among First-Line Treatments in Advanced Kidney Cancer
Perinephric Fat Deposits and Renal Tumorigenesis
Does Long Noncoding RNA Signature Have Prognostic Value in Kidney Cancer?
Bevacizumab Plus Immune Checkpoint Inhibition in Renal Cell Carcinoma
Identifying Renal Transplant Patients at Risk for Squamous Cell Carcinoma by DNA Methylation of T Cells
Metastatic Renal Cell Carcinoma: Sunitinib Alone Versus Nephrectomy
Targeting Metastases in Renal Cell Carcinoma With Stereotactic Radiation
Prevalence of Germline Mutations in Patients With Renal Cell Carcinoma
Distinguishing Subtypes of Kidney Cancer With Histologic Overlap
Lymph Node Dissection and Survival in High-Risk Kidney Cancer
Impact of Biopsychosocial Distress on Outcomes in Metastatic Kidney Cancer
Is There a Long-Term Benefit to TKIs Before Cytroreductive Nephrectomy?
Is Partial Nephrectomy Underused in Younger Patients With cT1 Renal Masses?
Identifying Risk Factors for Recurrence of Nonmetastatic Renal Cell Carcinoma
Relative Dose Intensity in First-Line Sunitinib Therapy for Metastatic Kidney Cancer
Is Neutrophil-Lymphocyte Ratio Predictive of Outcome After Surgery for Metastatic Kidney Cancer?
Potential Biomarker of Response to Sunitinib in Metastatic Kidney Cancer
Outcome Differences Based on Histopathology in Renal Cell Carcinoma
Tumor-Targeted Strategy for Overcoming Chemoresistance in Kidney Cancer
Health-Related Quality of Life With Pembrolizumab for Advanced Urothelial Cancer
Early Landmark Events for Patients Diagnosed With Clear Cell Renal Cell Carcinoma
Predictor of Response Rates to Anti–PD-1 Therapies Across Cancer Types
Timing of Sunitinib Schedule in Patients With Metastatic Renal Cell Carcinoma
Comparison of Nivolumab/Ipilimumab and Sunitinib in Advanced Kidney Cancer
DDR Genes and Response to Checkpoint Blockade in Urothelial Cancer
SABR as an Alternative to Cytoreductive Nephrectomy for Inoperable Kidney Cancer
Predicting Disease Recurrence in Localized Clear Cell Kidney Cancer
Genomic Alterations in Clear Cell Renal Cell Carcinoma and Response to Immune Checkpoint Inhibitors
Gene Discovery May Shed Light on Mechanism of Immunotherapy Resistance
Long-Term Outcomes With Atezolizumab in Metastatic Urothelial Carcinoma
Axitinib Plus Pembrolizumab in Advanced Kidney Cancer
METEOR Trial: Quality-of-Life Outcomes in Metastatic Kidney Cancer
Novel Diagnostic Technique for Clear Cell Renal Cell Carcinoma
Cost Sharing and Targeted Therapy Among Older Patients With Kidney Cancer
Crizotinib May Provide Disease Control in Advanced Papillary Renal Cell Carcinoma
Avelumab as Second-Line Treatment for Advanced Urothelial Carcinoma
Cabozantinib Versus Everolimus for Bone Metastases From Renal Cell Carcinoma
Familial Clustering of Bladder Cancer Regardless of Smoking History
Managing Cabozantinib-Related Adverse Events in Patients With Renal Cell Carcinoma
Novel Drug for Treatment of Advanced Clear Cell Renal Cell Carcinoma
Is Physical Inactivity an Independent Risk Factor for Renal Cancer?
Stereotactic Ablative Radiation for Renal Tumors
Renal Function With Ablative Techniques for Renal Mass in Solitary Kidney
miR-181a Upregulation and KLF6 Expression in Clear Cell Renal Cell Carcinoma
Recovery of Long-Term Renal Function After Radical Nephrectomy
Therapeutic Implications of Histologic Subtypes in Papillary Renal Cell Carcinoma
Perioperative Blood Transfusion and Prognosis After Surgery for Renal Cancer
Robotic-Assisted Surgery for Radical Nephrectomy: Outcomes and Costs
Potential Molecular Biomarker in Clear Cell Kidney Cancer
Activity and Safety of Tivozanib in Advanced Renal Cell Carcinoma
Post-Progression Response to Nivolumab in Advanced Renal Cell Carcinoma
Adjuvant Pazopanib After Surgery for Locally Advanced Renal Cell Carcinoma
Multigene Panel Testing in Identifying Hereditary Kidney Cancer
Bevacizumab Plus Novel Monoclonal Antibody in Metastatic Kidney Cancer
Sequence of Everolimus and Sunitinib in Metastatic Renal Cell Carcinoma
Can Dynamic Changes During Therapy Predict Survival in Renal Cell Cancer?
Predictive Marker in Nonmetastatic Renal Cell Carcinoma After Nephrectomy
Impact of Margin Status on Survival After Radical Nephrectomy
ALK Inhibitor MK-2206 Versus Everolimus in Refractory Renal Cell Carcinoma
Thyroid Dysfunction in Patients Receiving Immunotherapy for Advanced Kidney Cancer
Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma
Timing of Treatment for Advanced Kidney Cancer
Treatment Outcomes Based on Ethnicity in Metastatic Renal Cell Carcinoma
Combining Nephrectomy and SBRT for Advanced Kidney Cancer
MET Inhibitor Savolitinib in Advanced Papillary Renal Cell Cancer
Pembrolizumab as Second-Line Treatment for Advanced Urothelial Carcinoma
Impact of Everolimus-Induced Pneumonitis on Metastatic Renal Cell Carcinoma
Intermittent Sunitinib in Previously Untreated Metastatic Renal Cell Carcinoma
Vinflunine Maintenance in Advanced Urothelial Carcinoma
Adjuvant Treatment for High-Risk Clear Cell Renal Cancer
Targeted Therapies for Metastatic Chromophobe Renal Cell Carcinoma
Alternating Treatment Regimens in Clear Cell Renal Cell Cancer
Use of Metformin in Patients With Metastatic Renal Cell Carcinoma
Complete Surgical Metastasectomy in Metastatic Renal Cell Carcinoma
Pazopanib vs Paclitaxel in Advanced Urothelial Carcinoma
Potential Biomarker in Metastatic Renal Cell Carcinoma


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.